OncoMatch/Clinical Trials/NCT06696833
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Is NCT06696833 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including QH10304-BAL-01 and Fludarabine for b-cell acute lymphoblastic leukemia, adult.
Treatment: QH10304-BAL-01 · Fludarabine · Cyclophosphamide — This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
Disease stage
Required: Stage RELAPSED, REFRACTORY
Excluded: Stage ISOLATED EXTRAMEDULLARY RELAPSE
Meet the diagnosis of relapsed/refractory leukemia, excluding isolated extramedullary relapse
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: within 6 months before screening
Patients who have previously received CAR-T cell therapy within 6 months
Cannot have received: donor lymphocyte infusion
Exception: within 6 weeks before screening
donor lymphocyte infusion within 6 weeks before screening
Lab requirements
Kidney function
Creatinine ≤1.5×ULN
Liver function
Total bilirubin (TBil) ≤3×ULN, AST and ALT ≤3×ULN
Cardiac function
Left ventricular ejection fraction (LVEF) ≥50%
The vital organs function in accordance with the following requirements: 7.1Left ventricular ejection fraction (LVEF) ≥50%; 7.2Pulmonary function：normal oxygen saturation without oxygen supplementation; 7.3Total bilirubin (TBil) ≤3×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN； 7.4Creatinine ≤1.5×ULN;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06696833 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, donor lymphocyte infusion disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 positive expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages